Amyvid loses over half of its radioactivity every two hours because of which it must be distributed directly to imaging centers from the specialized radiopharmacies where it is produced.
Avid president and CEO, Lilly Amyvid global brand development leader Daniel Skovronsky said, "In the roughly two months since the approval of Amyvid, we have been working closely with imaging centers to ensure they are prepared to provide Amyvid to their customers."
Amyvid binds to amyloid plaques, one of the necessary pathological features of Alzheimer’s Disease, and is detecte using PET scan images of the brain.
A negative Amyvid scan indicates sparse to no amyloid plaques are currently present, which is inconsistent with a neuropathological diagnosis of Alzheimer’s Disease.
A positive Amyvid scan indicates moderate to frequent amyloid plaques are present, which is observed in patients with Alzheimer’s Disease and may also present in patients with other types of neurologic conditions and in older people with normal cognition.